Literature DB >> 30078813

Cholangiocarcinoma Trends, Incidence, and Relative Survival in Khon Kaen, Thailand From 1989 Through 2013: A Population-Based Cancer Registry Study.

Supot Kamsa-Ard1,2, Vor Luvira2,3, Krittika Suwanrungruang2,4, Siriporn Kamsa-Ard1,2, Varisara Luvira5, Chalongpon Santong4, Tharatip Srisuk3, Ake Pugkhem3, Vajarabhongsa Bhudhisawasdi3, Chawalit Pairojkul6.   

Abstract

BACKGROUND: Cholangiocarcinoma (CCA) is a common malignancy in northeastern Thailand. Over the last 4 decades, several policies have been implemented for its prevention, but there has been no update on the trends and relative survival (RS). Our aim was (a) to perform a statistical assessment of the incidence trends of CCA and project future trends, and (b) to estimate relative survival.
METHODS: All cases of CCA diagnosed from 1989 through 2013 were abstracted from the Khon Kaen Cancer Registry (KKCR). A jointpoint regression model was used to estimate the annual percentage change (APC) and to project future trends. We also calculated RS.
RESULTS: There were 11,711 cases of CCA. The incidence rate increased with an APC of 1.79% (95% confidence interval [CI], -0.2 to 3.8) from 1989 through 2002, and decreased with an APC of -6.09% (95% CI, -8.2 to -3.9) from 2002 through 2013. The projected incidence of CCA should stable over the next 10 years, albeit higher than the world rate. The respective 5-year RS for both sexes for age groups of 30-40, 41-45, 51-60, and 61-98 years was 22.3% (95% CI, 16.8-29.5), 14.3% (95% CI, 12.0-17.0), 8.6% (95% CI, 7.8-10.0), and 7.2% (95% CI, 6.4-8.0).
CONCLUSION: The incidence rate of CCA has decreased since 2002, representing a real decline in the risk of CCA. The incidence of CCA is projected to stabilize by 2025. The survival of patients with CCA remains poor.

Entities:  

Keywords:  cancer registry; cholangiocarcinoma; incidence; relative survival; trend

Mesh:

Year:  2018        PMID: 30078813      PMCID: PMC6445798          DOI: 10.2188/jea.JE20180007

Source DB:  PubMed          Journal:  J Epidemiol        ISSN: 0917-5040            Impact factor:   3.211


INTRODUCTION

Cholangiocarcinoma (CCA) is a major cause of cancer mortality around the world.[1] In Thailand, from 1988 through 2012, the respective age-standardized rate (ASR) of liver and bile duct cancer was between 53.4 and 94.8 per 100,000 for males and 18.5 and 39.4 per 100,000 for females. Among affected persons, CCA was the most common cell type, comprising between 82.0% and 89.0% of all detected primary liver cancers.[2]–[9] Several risk factors for CCA have been investigated in Thailand, but Opisthorchis viverrini is most often implicated in the genesis of CCA.[10]–[13] Since 1987, as a means of limiting the incidence of CCA, a number of government policies have been implemented to eradicate O. viverrini infection.[14] Treatment of CCA has also been improved through (a) better and more timely use of diagnostic technology, (b) refined surgical techniques, and (c) increasing the number of surgeons. We reported the declining trend in the incidence of CCA over the past 20 years, and hypothesized this trend represents a real reduced risk for CCA.[15] We attempted to use our reported data to simulate the predicted incidence of CCA in the future, but the reported incidence was not sufficiently stable. Therefore, we extended the period studied in order to (a) perform a statistical assessment of the incidence trends of CCA, (b) project future trends in the incidence of CCA, (c) evaluate the effectiveness of the control policies, and (d) evaluate whether the various treatment protocols have improved survival.

MATERIAL AND METHODS

Data for the study were from the Khon Kaen Cancer Registry (KKCR), a population-based cancer registry for Khon Kaen Province in northeastern Thailand. The KKCR began in 1985. According to estimates from the census data of the National Statistical Office for 2012[16] (available at URL: http://www.nso.go.th/), the KKCR contains data on 1.7 million patients comprising all cancer sites as per the International Agency for Research on Cancer (IARC) guidelines.[17] The KKCR has a completeness rating of 97.0%.[18] The sources of information for the cancer registry include databases from regional and community hospitals, pathology departments, and death certificates. The lag-time between diagnosis and reporting is less than 1 year, and only 3.2% of cases are based upon information from a death certificate only (DCO cases). All cases are encoded as per the International Classification of Diseases for Oncology, 3rd edition (ICD-O-3).[19]

Case definitions

The database was searched for all patients with CCA tumors living in Khon Kaen Province between January 1, 1989 and December 31, 2013. CCA is an ICD-O-3 diagnosis, and only the cases with coding C22.1, C24.0, C24.8, and C24.9 (excluding C24.1, Ampulla of Vater) were included.[20] Patients diagnosed from 1985 through 1988 were excluded because, at that time, registries were only just opening and the data lacked completeness, making the ASR unreliable.

Statistical methods

Percentages were used to describe proportions of the categorical data. The mean (standard deviation [SD]) was used to describe the continuous variables. Incidence trends were assessed using the estimated annual percentage change (APC) of the world ASRs. The Jointpoint regression program (version 4.0.4; The Surveillance, Epidemiology, and End Results [SEER] program of the National Cancer Institute [NCI], Rockville, MD, USA.)[21] was used to investigate the trends in the incidence rate of CCA, identify points where a significant change in the linear slope of the trends occurred, and the corresponding P-value and 95% confidence interval (CI) of the APC. We then determined the incidences of CCA in Khon Kaen Province from 1989 through 2013 and projected future trends from 2014 through 2030.[22] A maximum of one point was allowed in each regression. A value of 0.01 was added to all of the years in the data series for the dependent variable where a zero value was observed in 1 or more years. To determine survival, we calculated the follow-up time from diagnosis to the last known vital status of each patient; this was obtained by linking records between the Mortality Registry of Thailand[23] and the National Statistical Office[16] (updated to December 31, 2016). Focusing on stage of disease and period of time, the survival analysis was estimated using the Kaplan-Meier survival curve, and the log-rank test was used for between group comparisons.[24] Since the mean age at diagnosis of the neoplasms is high and other medical conditions may have influenced patient death, we also analyzed observed survival (OS) by stage of disease and period of diagnosis. In addition, we illustrated relative survival (RS), the ratio between observed survival (OS) and expected survival.[25] RS was analyzed and adapted from the Hakulinen method.[26],[27] RS was estimated using the mortality tables for Khon Kaen Province. The results for RS were corrected for mortality by causes other than cancer, especially in older populations. All statistical tests were two-sided with a significance level of 0.05. No adjustment of the alpha level was made for multiple testing. All statistical analyses were implemented using the Stata release 10 (StataCorp LLC, College Station, TX, USA).[28]

Data processing

Data were recorded using CanReg 5 software provided by the IARC (International Agency for Research on Cancer, Lyon, France).[29] The verification was performed with necessary correction, including logic, range, and internal consistency, which were checked using Stata 10.0 Statistical Software (Stata Corp)[28] and Epidata Software (The EpiData Association, Denmark).[30]

Ethical considerations

The present study was approved by the Institutional Review Board (HE581074), under the Office of Human Research Ethics, Khon Kaen University.

RESULTS

Descriptive epidemiology

We identified 11,711 cases of CCA in the KKCR database for the period 1989 through 2013. The male to female ratio was 2.2:1. The mean age was 62.6 (SD, 11.2) years. The age at diagnosis trended to be high. The other variables did not vary significantly. The most common stage of disease was ‘unknown staging’ (76.2%; n = 8,927) and “late stage” (ie, Stage III and IV; 23.3%; n = 2,722). Histological grading was commonly missing from the data (97.5%; n = 11,414) (Table 1). The primary bases of diagnosis were endoscopic and radiologic evidence versus morphological verification (10.6%; n = 1,247) (ie, based on either cytological or histological examination of tissue from the primary site, %MV) (data not shown).
Table 1.

Characteristics of study participants at recruitment by 5-year periods

Characteristic1989–19931994–19981999–20032004–20082009–2013





n%n%n%n%n%
1. Sex
 Males1,29569.71,35670.91,92568.051,83868.21,59866.2
 Females56430.355729.190431.9585731.881733.8
Male to female ratio; 2.2:11.3:12.4:12.1:12.1:12.1:1
2. Age at diagnosis, year of age
 30–401045.6754.0943.3622.3341.4
 41–5030016.229115.334412.228110.51727.1
 51–6063033.961131.975426.773727.453222.0
 61–9882544.393648.81,63757.81,61559.81,67769.5
 Mean (SD) = 62.6 (11.2)59.0 (10.9)60.2 (10.8)62.1 (10.9)63.1 (10.8)65.7 (10.6)
 Median (Min: Max) = 63 (30:98)59.0 (30:92)60.0 (30:94)63.0 (30:97)64.0 (30:96)66.0 (30:98)
3. Stage at diagnosis
 Stage I50.3140.2
 Stage II20.1140.5140.6
 Stage III30.220.1150.6411.7
 Stage IV44624.039420.656019.865424.560725.1
 Unknown1,41075.81,51279.02,26780.11,98974.41,74972.4
4. Histological grading
 Well-differentiated110.6612.2542.0522.2
 Moderately-differentiated10.1210.7220.8241.0
 Poorly-differentiated10.1200.7140.5120.5
 Undifferentiated120.11
 Unknown1,858100.01,901100.02,72696.42,60396.52,32696.3

Incidence

Age-standardized incidence rates (ASR)

The respective ASR rate per 100,000 for CCA for (a) males, (b) females, and (c) males and females from 1989 through 2013 ranged from (a) 25.2 to 58.8, (b) 9.9 to 23.6, and (c) 17.5 to 39.9 (Figure 1). Thus, the overall ASR per 100,000 was 41.5 for males (95% CI, 40.6–42.4), 16.6 for females (95% CI, 16.1–17.1), and 28.1 for males and females (95% CI, 27.6–28.7) (Figure 1).
Figure 1.

Incidence rates (per 100,000 per year) for CCA by sex in Khon Kaen Province from 1989 through 2013.

The ASR for CCA for all age groups, both males and females, for the whole period (1989 through 2013) has significantly decreased over time. The exception was for patients between 61 and 98 years, for whom the ASR initially increased in the first three periods but decreased in the last two (Table 2).
Table 2.

Incidence by time period, age group, and sex in Khon Kaen Province from 1989 through 2013

CharacteristicPeriod of timeMalesFemalesBoth sexes




Age group, yearsnCRASR95% CInCRASR95% CInCRASR95% CI
30–401989–1993531.231.10.77 to 1.34250.610.50.30 to 0.69780.960.770.6 to 0.95
1994–1998390.930.70.48 to 0.92130.310.20.10 to 0.35520.620.50.33 to 0.85
1999–2003521.220.90.64 to 1.12170.390.30.15 to 0.41690.800.60.44 to 0.71
2004–2008320.760.60.38 to 0.78130.300.20.10 to 0.34450.530.40.28 to 0.51
2009–2013210.500.40.24 to 0.6050.110.10.01 to 0.18260.300.30.15 to 0.35
41–501989–19931914.45.24.44 to 5.92822.02.21.72 to 2.682733.673.73.23 to 4.11
1994–19981984.734.74.07 to 5.39641.521.51.12 to 1.852623.123.12.71 to 3.76
1999–20032124.964.33.74 to 4.91872.011.81.40 to 2.152993.473.02.68 to 3.37
2004–20081844.383.52.95 to 3.95591.351.10.79 to 1.332432.842.21.94 to 2.50
2009–20131112.661.91.58 to 2.31400.930.60.44 to 0.831511.971.41.22 to 1.65
51–601989–199342912.5216.114.73 to 17.451633.984.53.85 to 5.245927.268.67.87 to 9.25
1994–199841013.0214.012.83 to 15.181633.874.03.36 to 4.575736.827.26.59 to 7.77
1999–200351912.1411.510.47 to 12.442004.614.23.61 to 4.767196.656.25.65 to 6.66
2004–200849511.799.208.36 to 9.981964.493.42.93 to 3.886918.076.195.73 to 6.66
2009–20133317.925.24.66 to 5.791463.282.11.78 to 2.474775.533.63.29 to 3.94
61–981989–199361414.2323.421.4 to 25.342937.1611.19.84 to 12.4090711.1318.517.32 to 19.74
1994–199870516.8526.324.37 to 28.253157.479.88.71 to 10.88102012.417.316.25 to 18.37
1999–2003113621.6128.526.62 to 30.2859813.7814.913.70 to 16.09173411.8414.113.28 to 15.02
2004–2008112526.7927.225.57 to 28.7458713.4411.510.55 to 12.42171219.9918.517.67 to 19.43
2009–2013113427.1321.320.9 to 22.5862614.089.48.69 to 10.19176020.4014.814.1 to 15.50

ASR, age-standardize rate; CI, confidence interval; CR, crude rate.

ASR, age-standardize rate; CI, confidence interval; CR, crude rate. Focusing on all ages, for the period 1989 through 2013, the Joinpoint regression revealed that the incidence was significantly decreasing by: (a) −2.0% per year among males (average annual percent change [AAPC] −2.0; 95% CI, −3.4 to −0.6); (b) −1.5% per year among females (AAPC −1.5; 95% CI, −3.1 to 0.1); and, (c) −1.9% per year among males and females (AAPC −1.9%; 95% CI, −3.3 to −0.5). Accoding to the Joinpoint analysis of years, the incidence rate among males increased with an APC of 1.7% (95% CI, −0.3 to 3.7) from 1989 through 2002, and decreased with an APC of 6.2% (95% CI, −8.4 to −4.0). By comparison, among females the incidence rate increased with an APC of 2.2% (95% CI, −0.2 to 4.6) from 1989 through 2002, and decresed with an APC of 5.7% (95% CI, −8.1 to −3.1) (Figure 2a and Figure 2b). The simulated projection curve of CCA incidence from 2014 through 2030 indicates that rates are expected to continue to decrease to 17.5 per 100,000 in males. Females are expected to reach 7.7 per 100,000, while both sexes are predicted to reach 12.2 per 100,000. The incidence will be stable over the next 10 years but will still exceed the average worldwide incidence (Figure 2c).
Figure 2.

Joinpoint trends for age-adjusted rates per 100,000 for CCA in Khon Kaen Province from 1989–2002 and 2002–2013. a) Males; b) Females, and c) Simulated CCA incidence trend projections to 2030. ASR, age standardized rate.

Lastly, for boths males and females, the incidence rate increased 1.8% (95% CI, −0.2 to 3.8) from 1989 through 2002, and decreased with an APC of 6.1% (95% CI, −8.2 to −3.9) (Table 3).
Table 3.

Number of cases and annual percentage of change in incidence rate of CCA in Khon Kean Province from 1989 through 2013

CharacteristicPeriod of timeMalesFemalesBoth sexes




All agesnAPC95% CI, P-valuenAPC95% CI, P-valuenAPC95% CI, P-value
 1989–20024,1561.70(−0.3 to 3.7), 0.1001,8232.19(−0.2 to 4.6), 0.1005,9791.79(−0.2 to 3.8), 0.100
 2002–20133,856−6.24(−8.4 to −4.0), <0.0011,876−5.71(−8.1 to −3.2), <0.0015,732−6.09(−8.2 to −3.9), <0.001

APC, annual percentage change; CI, confidence interval.

APC, annual percentage change; CI, confidence interval. Figure 3 illustrates the incidence of CCA was declining parallel with the prevalence of O. viverrini. The data from the national and local level reveal a decreasing proportion of infection, which is consistent with the ASR for CCA in Thailand.
Figure 3.

Age-adjusted rates per 100,000 (both sexes, ASR), OV (%)-Thailand, and OV (%)-KK in Khon Kaen Province trend downward. ASR, age standardized rate; KK, Khon Kaen Province; OV, Opisthorchis viverrini.

Survival

The respective OS versus RS at 1, 3, and 5 years for the different age groups of CCA is presented in Table 4. At 5 years, the respective OS and RS for males aged 30–40, 41–50, 51–60, and 61–98 years of age was 23.2% (95% CI, 17.0 to 30.4%) versus 23.4% (95% CI, 17.1 to 31.6%), 12.6% (95% CI, 10.1 to 15.7%) versus 13.1% (95% CI, 10.5 to 16.2%), 7.4% (95% CI, 6.0 to 9.0%) versus 7.7% (95% CI, 6.2 to 9.2%), and 6.8% (95% CI, 5.9 to 7.8%) versus 6.9% (95% CI, 6.0 to 7.9%). For females, the respective OS versus RS for age groups of 30–40, 41–50, 51–60, and 61–98 years of age was 19.0% (95% CI, 10.2 to 35.4%) versus 19.2% (95% CI, 10.3 to 35.7%), 16.7% (95% CI, 12.3 to 22.5%) versus 17.5% (95% CI, 13.2 to 23.4%), 11.1% (95% CI, 8.7 to 14.1%) versus 11.2% (95% CI, 8.8 to 14.2%), and 7.6% (95% CI, 6.4 to 9.1%) versus 7.7% (95% CI, 6.4 to 9.2%) (Table 4).
Table 4.

Overall observed survival and relative survival of CCA for each age-group and sex in Khon Kaen Province from 1989 through 2013

CharacteristicSurvival timeMalesFemalesBoth sexes




Age groups, yearsnOS (95% CI)RS (95% CI)nOS (95% CI)RS (95% CI)nOS (95% CI)RS (95% CI)
30–401 year4935.5 (28.5 to 44.1)36.3 (29.3 to 45.1)1938.7 (27.6 to 54.3)41.0 (29.6 to 56.6)6837.0 (30.9 to 44.3)37.7 (31.5 to 45.0)
3 years2825.2 (18.8 to 33.6)26.4 (19.9 to 34.9)1124.9 (15.2 to 40.8)25.1 (15.3 to 41.2)3925.1 (20.2 to 33.7)26.1 (20.4 to 33.3)
5 years2323.2 (17.0 to 30.4)23.4 (17.2 to 31.6)719.0 (10.2 to 35.4)19.2 (10.3 to 35.7)2522 (16.6 to 29.2)22.3 (16.8 to 29.5)
41–501 year14124.8 (21.6 to 28.4)25.1 (21.9 to 28.7)6126.6 (21.5 to 32.9)27.6 (22.4 to 34.0)20225.5 (22.8 to 28.6)25.7 (23.0 to 28.8)
3 years6813.8 (11.3 to 17.0)13.9 (11.4 to 17.1)3718.0 (13.6 to 23.8)18.1 (13.7 to 24.0)10514.9 (12.6 to 17.7)15.1 (12.8 to 17.8)
5 years4012.6 (10.1 to 15.7)13.1 (10.5 to 16.2)2316.7 (12.3 to 22.5)17.5 (13.2 to 23.4)6313.7 (11.4 to 16.4)14.3 (12.0 to 17.0)
51–601 year28419.3 (17.4 to 21.3)19.4 (17.6 to 21.5)13523.1 (20.0 to 26.6)23.3 (20.2 to 26.8)41920.4 (18.8 to 22.2)20.5 (18.9 to 22.3)
3 years1089.2 (7.9 to 10.9)9.4 (8.0 to 11.0)6213.3 (10.8 to 16.4)13.6 (11.1 to 16.7)17010.4 (9.1 to 11.8)10.6 (9.3 to 12.0)
5 years467.4 (6.0 to 9.0)7.6 (6.2 to 9.2)4011.1 (8.7 to 14.1)11.2 (8.8 to 14.2)868.5 (7.3 to 9.9)8.6 (7.8 to 10.0)
61–981 year53416.8 (15.6 to 18.1)16.8 (15.6 to 18.1)32919.4 (17.7 to 21.3)19.5 (17.7 to 21.4)86317.7 (16.7 to 18.7)17.7 (16.7 to 18.8)
3 years2278.6 (7.7 to 9.7)8.7 (7.8 to 9.8)1259.8 (8.4 to 11.3)9.9 (8.5 to 11.5)3529.1 (8.3 to 9.9)9.1 (8.3 to 10.0)
5 years1146.8 (5.9 to 7.8)6.9 (6.0 to 7.9)647.6 (6.4 to 9.1)7.7 (6.4 to 9.2)1747.1 (6.4 to 7.9)7.2 (6.4 to 8.0)

CI, confidence interval; OS, overall survival; RS, relative survival.

CI, confidence interval; OS, overall survival; RS, relative survival. Focusing on stage of disease and period of time, the results of the log-rank test showed significant relationships between patient survival and stage of disease and period of time (P-value <0.001) (Figure 4 and Figure 5).
Figure 4.

Kaplan-Meier survival curves for patients with CCA in Khon Kaen Province from 1989 through 2013. The curves represent the TMN stage.

Figure 5.

Kaplan-Meier survival curves for males (a) and females (b) with CCA in Khon Kaen Province from 1989 through 2013. The curves represents periods of time. CI, confidence interval.

DISCUSSION

The current study showed that the incidence of CCA has been significantly decreasing by (a) −2.0% per year among males, (b) −1.50% per year among females, and (c) −1.9 per year among males and females. This is consistent with the reported incidence in our previous study and the ASR of liver and bile duct cancer as reported by the Thailand Cancer Registry. The most common histological type was CCA.[2]–[9] We have hypothesized that the decline in the incidence of CCA in our previous study may be the real falling risk.[15] The updated decline in incidence confirms our hypothesis. The decrease in the incidence of CCA might be the result of controlling the risk factors associated with O. viverrini infection. The incidence of O. viverrini infection has been decreasing over time, from >60% in 1984 to <10% after 1997.[31] The declining incidence parallels a decline in O. viverrini infection rates over the last 20 years. Several studies have addressed the unique risk factors of CCA in some countries.[32] Since O. viverrini infection is believed to be one of the risk factors of cholangiocarcinogenesis in Thailand,[33] a process that takes decades, time was also needed to evaluate the effectiveness of O. viverrini infection control (Figure 3). Numerous government policies aimed at decreasing the rate of O. viverrini infection, including: (a) liver fluke control units, established in 1967; (b) continuous health education, also established in 1967; (c) a liver fluke control program, embedded in the 5-year National Public Health Development Plan (1987–1991)[34]; and (d) the Promotion of Community Health through Parasitic Control in seven northeastern provinces, in cooperation with the Federal Republic of Germany government, run from 1989–1992. The liver fluke control program continues to be an element of the National Public Health Developmant Plan.[14],[31] Our data show that, while the elderly continue to eat raw fish, the younger generations are avoiding eating it. The results indicate that O. viverrini infection occurred predominantly in the elderly over younger age groups.[35] Education appears to be more effective in the young than the elderly. The life cycle of O. viverrini and risk factors for CCA should thus be introduced in primary school. We found that the predicted incidence of CCA will be stable over the next 10 years, albeit higher than in other parts of the world,[36] suggesting that there are unidentified risk factors other than O. viverrini infection and nitrosamine. With respect to the latter factor, in other research, we attempted to demonstrate that repeated use of praziquantel could increase the risk of CCA, but the evidence was weak.[37] Further research is needed to identify other risk factors for CCA, particularly other environmental factors that could be controlled (ie, pesticides and carcinogens in the food chain). The survival of CCA patients remains poor, despite improvements in diagnostic technology and surgical techniques. Several reasons may account for this finding: (a) most patients in northeastern Thailand present for care at a late stage of CCA, when only palliative treatment is an option[38]; (b) stringent criteria for resection means that some patients are denied surgery; and (c) after 2006, a new classification of bile duct tumors (ie, intraductal papillary neoplasm of the bile duct [IPNB]) was introduced, which was previously included with CCA. Since the prognosis of IPNB is relatively good, the survival of CCA before 2006 appeared to have been better than after IPNB was no longer included as a CCA.[39],[40]

Conclusion

The incidence of CCA in Khon Kaen Province has been decreasing over the last 10–12 years, coinciding with government efforts to control risk factors related to O. viverrini infection. The projected incidence of CCA should remain stable over the next 10 years, although it is higher than the worldwide incidence. The survival of CCA patients remains poor, so it is important to identify other risk factors, apart from O. viverrini and nitrosamine, that could be targeted to lower the incidence, as well as employing a screening program to detect eartlier stage that might improve survival.
  17 in total

1.  Quality of case ascertainment in cancer registries: a proposal for a virtual three-source capture-recapture technique.

Authors:  Krittika Suwanrungruang; Hutcha Sriplung; Pattarawin Attasara; Somnuk Temiyasathit; Rangsiya Buasom; Narate Waisri; Karnchana Daoprasert; Supot Kamsa-Ard; Cheamchit Tasanapitak
Journal:  Asian Pac J Cancer Prev       Date:  2011

2.  Long-term outcome of surgical resection for intraductal papillary neoplasm of the bile duct.

Authors:  Vor Luvira; Ake Pugkhem; Vajarabhongsa Bhudhisawasdi; Chawalit Pairojkul; Egapong Sathitkarnmanee; Varisara Luvira; Supot Kamsa-Ard
Journal:  J Gastroenterol Hepatol       Date:  2017-02       Impact factor: 4.029

3.  Choosing the relative survival method for cancer survival estimation.

Authors:  Timo Hakulinen; Karri Seppä; Paul C Lambert
Journal:  Eur J Cancer       Date:  2011-05-04       Impact factor: 9.162

4.  Risk of bile duct cancer among printing workers exposed to 1,2-dichloropropane and/or dichloromethane.

Authors:  Tomotaka Sobue; Mai Utada; Takeshi Makiuchi; Yuko Ohno; Shinichiro Uehara; Tomoshige Hayashi; Kyoko Kogawa Sato; Ginji Endo
Journal:  J Occup Health       Date:  2015-02-07       Impact factor: 2.708

5.  Liver diseases in Thailand. An analysis of liver biopsies.

Authors:  N Bhamarapravati; V Virranuvatti
Journal:  Am J Gastroenterol       Date:  1966-04       Impact factor: 10.864

6.  Epidemiology of opisthorchiasis and national control program in Thailand.

Authors:  P Jongsuksuntigul; T Imsomboon
Journal:  Southeast Asian J Trop Med Public Health       Date:  1998-06       Impact factor: 0.267

7.  Cholangiocarcinoma Patient Outcome in Northeastern Thailand: Single-Center Prospective Study.

Authors:  Vor Luvira; Kasama Nilprapha; Vajarabhongsa Bhudhisawasdi; Ake Pugkhem; Nittaya Chamadol; Supot Kamsa-ard
Journal:  Asian Pac J Cancer Prev       Date:  2016

8.  Repeated exposure to Opisthorchis viverrini and treatment with the antihelminthic Praziquantel lacks carcinogenic potential.

Authors:  W Thamavit; M A Moore; S Ruchirawat; N Ito
Journal:  Carcinogenesis       Date:  1992-02       Impact factor: 4.944

9.  Morphological Classification of Intraductal Papillary Neoplasm of the Bile Duct with Survival Correlation

Authors:  Vor Luvira; Kulyada Somsap; Ake Pugkhem; Chalerm Eurboonyanun; Varisara Luvira; Vajarabhongsa Bhudhisawasdi; Chawalit Pairojkul; Supot Kamsa Ard
Journal:  Asian Pac J Cancer Prev       Date:  2017-01-01

Review 10.  Risk Factors for Cholangiocarcinoma in Thailand: A Systematiczzm321990Review and Meta-Analysis

Authors:  Siriporn Kamsa-ard; Supot Kamsa-ard; Vor Luvira; Krittika Suwanrungruang; Patravoot Vatanasapt; Surapon Wiangnon
Journal:  Asian Pac J Cancer Prev       Date:  2018-03-27
View more
  15 in total

Review 1.  Cholangiocarcinoma 2020: the next horizon in mechanisms and management.

Authors:  Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-06-30       Impact factor: 46.802

2.  Aberrant GLUT1 Expression Is Associated With Carcinogenesis and Progression of Liver Fluke-associated Cholangiocarcinoma.

Authors:  Ubonrat Thamrongwaranggoon; Sakkarn Sangkhamanon; Wunchana Seubwai; Paksiree Saranaruk; Ubon Cha'on; Sopit Wongkham
Journal:  In Vivo       Date:  2021 Jan-Feb       Impact factor: 2.155

3.  Cost-effectiveness evaluation of different control strategies for Clonorchis sinensis infection in a high endemic area of China: A modelling study.

Authors:  Yun-Ting He; Xiao-Hong Huang; Yue-Yi Fang; Qing-Sheng Zeng; Lai-De Li; Le Luo; Ying-Si Lai
Journal:  PLoS Negl Trop Dis       Date:  2022-05-23

4.  Probing the Anti-Cancer Potency of Sulfated Galactans on Cholangiocarcinoma Cells Using Synchrotron FTIR Microspectroscopy, Molecular Docking, and In Vitro Studies.

Authors:  Boonyakorn Boonsri; Kiattawee Choowongkomon; Buabarn Kuaprasert; Thanvarin Thitiphatphuvanon; Kittiya Supradit; Apinya Sayinta; Jinchutha Duangdara; Tawut Rudtanatip; Kanokpan Wongprasert
Journal:  Mar Drugs       Date:  2021-04-30       Impact factor: 5.118

5.  Decreasing trends in cholangiocarcinoma incidence and relative survival in Khon Kaen, Thailand: An updated, inclusive, population-based cancer registry analysis for 1989-2018.

Authors:  Supot Kamsa-Ard; Chalongpon Santong; Siriporn Kamsa-Ard; Vor Luvira; Varisara Luvira; Krittika Suwanrungruang; Vajarabhongsa Bhudhisawasdi
Journal:  PLoS One       Date:  2021-02-16       Impact factor: 3.240

6.  Infrahepatic Inferior Vena Cava Clamping Reduces Blood Loss during Liver Transection for Cholangiocarcinoma.

Authors:  Natwutpong Leeratanakachorn; Vor Luvira; Theerawee Tipwaratorn; Suapa Theeragul; Apiwat Jarearnrat; Attapol Titapun; Tharatip Srisuk; Supot Kamsa-Ard; Ake Pugkhem; Narong Khuntikeo; Chawalit Pairojkul; Vajarabhongsa Bhudhisawasdi
Journal:  Int J Hepatol       Date:  2021-08-26

7.  Diagnostic and Prognostic Value of Circulating Cell-Free DNA for Cholangiocarcinoma.

Authors:  Preawwalee Wintachai; Jing Quan Lim; Anchalee Techasen; Worachart Lert-Itthiporn; Sarinya Kongpetch; Watcharin Loilome; Jarin Chindaprasirt; Attapol Titapun; Nisana Namwat; Narong Khuntikeo; Apinya Jusakul
Journal:  Diagnostics (Basel)       Date:  2021-05-30

Review 8.  Omics-Based Platforms: Current Status and Potential Use for Cholangiocarcinoma.

Authors:  Yu-Chan Chang; Ming-Huang Chen; Chun-Nan Yeh; Michael Hsiao
Journal:  Biomolecules       Date:  2020-09-28

9.  Phase I clinical trial to evaluate the safety and pharmacokinetics of capsule formulation of the standardized extract of Atractylodes lancea.

Authors:  Kesara Na-Bangchang; Inthuorn Kulma; Tullayakorn Plengsuriyakarn; Thipaporn Tharavanij; Kanawut Kotawng; Anurak Chemung; Nadda Muhamad; Juntra Karbwang
Journal:  J Tradit Complement Med       Date:  2021-02-04

10.  Homophilic Interaction of CD147 Promotes IL-6-Mediated Cholangiocarcinoma Invasion via the NF-κB-Dependent Pathway.

Authors:  Paweena Dana; Ryusho Kariya; Worachart Lert-Itthiporn; Wunchana Seubwai; Saowaluk Saisomboon; Chaisiri Wongkham; Seiji Okada; Sopit Wongkham; Kulthida Vaeteewoottacharn
Journal:  Int J Mol Sci       Date:  2021-12-16       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.